HCW Biologics Net Worth
HCW Biologics Net Worth Breakdown | HCWB |
HCW Biologics Net Worth Analysis
HCW Biologics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including HCW Biologics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of HCW Biologics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform HCW Biologics' net worth analysis. One common approach is to calculate HCW Biologics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares HCW Biologics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing HCW Biologics' net worth. This approach calculates the present value of HCW Biologics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of HCW Biologics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate HCW Biologics' net worth. This involves comparing HCW Biologics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into HCW Biologics' net worth relative to its peers.
Enterprise Value |
|
To determine if HCW Biologics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding HCW Biologics' net worth research are outlined below:
| HCW Biologics is way too risky over 90 days horizon | |
| HCW Biologics has some characteristics of a very speculative penny stock | |
| HCW Biologics appears to be risky and price may revert if volatility continues | |
| HCW Biologics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.84 M. Net Loss for the year was (24.99 M) with profit before overhead, payroll, taxes, and interest of 4.1 M. | |
| HCW Biologics currently holds about 32.41 M in cash with (22.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 52.0% of the company shares are held by company insiders | |
| Latest headline from benzinga.com: Why Keysight Technologies Shares Are Trading Higher By Over 9 Here Are 20 Stocks Moving Premarket |
HCW Biologics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in HCW Biologics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to HCW Biologics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know HCW Biologics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as HCW Biologics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading HCW Biologics backward and forwards among themselves. HCW Biologics' institutional investor refers to the entity that pools money to purchase HCW Biologics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-06-30 | 21.4 K | Citadel Advisors Llc | 2024-06-30 | 13.9 K | Northern Trust Corp | 2024-09-30 | 10.2 K | Tower Research Capital Llc | 2024-06-30 | 6.2 K | Ubs Group Ag | 2024-06-30 | 4.3 K | Royal Bank Of Canada | 2024-06-30 | 407 | Bank Of America Corp | 2024-06-30 | 156 | Wells Fargo & Co | 2024-06-30 | 0.0 | Jpmorgan Chase & Co | 2024-06-30 | 0.0 | Honkamp Krueger Financial Services Inc | 2024-09-30 | 279.5 K | Hightower Advisors, Llc | 2024-06-30 | 180.8 K |
Follow HCW Biologics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.95 M.Market Cap |
|
Project HCW Biologics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.88) | (0.92) | |
| Return On Capital Employed | (1.30) | (1.37) | |
| Return On Assets | (0.88) | (0.92) | |
| Return On Equity | (1.86) | (1.76) |
When accessing HCW Biologics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures HCW Biologics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of HCW Biologics' profitability and make more informed investment decisions.
Please note, the presentation of HCW Biologics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, HCW Biologics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of HCW Biologics' management manipulating its earnings.
Evaluate HCW Biologics' management efficiency
HCW Biologics has return on total asset (ROA) of (0.7009) % which means that it has lost $0.7009 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4432) %, meaning that it created substantial loss on money invested by shareholders. HCW Biologics' management efficiency ratios could be used to measure how well HCW Biologics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.92. In addition to that, Return On Capital Employed is expected to decline to -1.37. At present, HCW Biologics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 45.2 M, whereas Non Current Assets Total are forecasted to decline to about 11.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.37 | 0.56 | |
| Tangible Book Value Per Share | 0.37 | 0.56 | |
| Enterprise Value Over EBITDA | (1.99) | (2.09) | |
| Price Book Value Ratio | 3.28 | 3.12 | |
| Enterprise Value Multiple | (1.99) | (2.09) | |
| Price Fair Value | 3.28 | 3.12 | |
| Enterprise Value | 46.9 M | 62.6 M |
Effective management at HCW Biologics has been a driving force behind its market achievements. We assess the correlation between management practices and financial success to determine the stock's value.
Enterprise Value Revenue 11.054 | Revenue 3.9 M | Quarterly Revenue Growth (0.01) | Revenue Per Share 0.107 | Return On Equity (3.44) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific HCW Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on HCW Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases HCW Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
HCW Biologics time-series forecasting models is one of many HCW Biologics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary HCW Biologics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
HCW Biologics Earnings per Share Projection vs Actual
HCW Biologics Corporate Management
| Hing Wong | CEO, Founder | Profile | |
| Lee Flowers | Senior Development | Profile | |
| Peter Rhode | Chief Operations | Profile | |
| Nicole Esq | Vice Affairs | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HCW Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 0.107 | Quarterly Revenue Growth (0.01) | Return On Assets (0.70) | Return On Equity (3.44) |
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.